Table 3.

List of antibodies that received authorization for COVID-19 treatment up to November 2022.

No	Antibodies Name	Current Status	References
1	Bebtelovimab	Remain authorized in the U.S. until further notice by the FDA.	[30,83]
2	Tixagevimab with cilgavimab	Remain authorized with the recommendation of repeat dosing every six months with a dose of 300 mg of tixagevimab and 300 mg of Cilgavimab.	[84,85]
3	Sotrovimab	Since 5 April 2022, no longer authorized in any U.S. region; approved in Australia, the UK, and the EU.	[86,87,88]
4	Bamlanivimab with etesevimab	Pausing all distribution.	[81,89]
5	Casirivimab with imdevimab	Currently not authorized in any U.S. region; however, it is recommended to be retained for future SARS-CoV-2 variants that may be susceptible.	[33,88,90]
6	Amubarvimab/romlusevimab	Approved in China.	[88]
7	Regdanvimab (CT-P59)	Approved in the Republic of Korea and the EU.	[88]
8	Ronapreve	Approved in Japan, the UK, the EU, and Australia.	[88]
9	F61	Approved for clinical trials in China.	[91]
10	Tocilizumab	Authorized for emergency use in June 2021.	[92,93]
11	Sarilumab	Clinical trial phase 3.	[94]
12	Adalimumab	Clinical trial phase 3.	[95]
13	Canakinumab	Clinical trial phase 3.	[96]
14	Ravulizumab	Completed clinical phase 3; recruiting phase 4 trials.	[97,98]
15	Lenzilumab	Clinical trial phase 3.	[99]

Abbreviation: EUA, emergency use authorization; FDA, U.S. Food and Drug Administration; mg, milligram.